Vision Incubate Invests in CAR-T Drug Discovery Firm Optium Biotechnologies

Vision Incubate Co., Ltd. invested in Optium Biotechnologies, Inc. in April 2026. Optium is a biotech company driving drug discovery research using the 'Eumbody System,' a CAR array generation technology originating from Ehime University. They are currently preparing for clinical trials of 'OPTF01,' an anti-FAPa CAR-T cell that targets tumor cells and the tumor microenvironment.

The investment aligns with Vision Incubate's mission to bridge academia-based research results to societal implementation, given their high assessment of Optium's innovative technology. This funding will accelerate preparations for starting US clinical trials for glioblastoma. Optium aims to provide new treatment options for intractable solid tumors.